Johnson & Johnson (NYSE:JNJ) is Beddow Capital Management Inc.’s 8th Largest Position

Beddow Capital Management Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 42,233 shares of the company’s stock after selling 223 shares during the period. Johnson & Johnson accounts for about 3.9% of Beddow Capital Management Inc.’s holdings, making the stock its 8th biggest holding. Beddow Capital Management Inc.’s holdings in Johnson & Johnson were worth $7,485,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. Family CFO Inc purchased a new position in Johnson & Johnson in the 4th quarter valued at about $26,000. Steward Financial Group LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at about $34,000. Joseph P. Lucia & Associates LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $38,000. Advocacy Wealth Management Services LLC raised its stake in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $49,000. 68.78% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

NYSE JNJ opened at $174.59 on Thursday. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.14. The firm has a market capitalization of $459.42 billion, a PE ratio of 25.41, a P/E/G ratio of 3.31 and a beta of 0.59. The company’s 50 day simple moving average is $175.57 and its 200 day simple moving average is $174.49.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The business had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same quarter last year, the business earned $2.48 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. As a group, equities research analysts forecast that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.59%. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent analyst reports. Citigroup cut their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Daiwa Capital Markets began coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating on the stock. SVB Leerink dropped their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Credit Suisse Group increased their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Finally, UBS Group dropped their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.